| Literature DB >> 28860519 |
Tingting Liu1,2,3, Panpan Hu1,2,3, Ruihua Cao4, Xing Ye5, Yanghua Tian1,2,3, Xianwen Chen6,7,8, Kai Wang9,10,11,12.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder pathologically characterized by a selective loss of dopaminergic neurons in the substantia nigra. In previous studies, greater attention was paid to impairments in motor disturbances in contrast to impairments of cognitive function in PD that was often ignored. In present study, a duration discrimination paradigm was used to assess global and local biological motion (BM) perception in healthy controls(HCs) and PD patients with and without dopamine substitution treatment (DST). Biological motion sequences and inanimate motion sequences (inverted BM sequences) were sequentially presented on a screen. Observers were required to verbally make a 2-alternative forced-choice to indicate whether the first or second interval appeared longer. The stimuli involved global and local BM sequences. Statistical analyses were conducted on points of subjective equality (PSE). We found significant differences between untreated PD patients and HCs as well as differences between global and local BM conditions. PD patients have a deficit in both global and local BM perception. Nevertheless, these two BM conditions can be improved under DST. Our data indicates that BM perception may be damaged in PD patients and dopaminergic medication is conducive to maintain the BM perception in PD patients.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28860519 PMCID: PMC5579208 DOI: 10.1038/s41598-017-10463-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic Data, Clinical characteristics and Neuropsychological Findings of PD and HCs (Mean ± Standard Deviation).
| PD | HCs | |
|---|---|---|
| Number | 25 | 25 |
| Age (years) | 61.96 ± 7.92 | 60.60 ± 9.49 |
| Gender (M/F) | 16/9 | 19/6 |
| Education Background (year) | 7.76 ± 4.24 | 7.32 ± 3.60 |
| Disease duration (years) | 3.70 ± 1.93 | — |
| onset side (left/right) | 14/11 | — |
| Hoehn and Yahr stage | ||
| Stage 1.5 | 8 | — |
| Stage 2.0 | 10 | — |
| Stage 2.5 | 4 | — |
| Stage 3.0 | 3 | — |
| MMSE score (out of 30) | 27.92 ± 1.50 | 27.56 ± 1.73 |
| VFT* | 11.56 ± 1.58 | 13.12 ± 2.19 |
| DS(f)* (out of 8) | 5.56 ± 0.71 | 6.12 ± 0.93 |
| DS(b)* (out of 7) | 3.52 ± 0.65 | 4.20 ± 0.87 |
PD = Parkinson’s Disease; HCs = Health controls; DS (b) = Digital Span (backward); VFT = verbal fluency task; DS (f) = Digital Span (forward); MMSE = mini-mental state examination. *Indicates a significant effect of group (p < 0.05).
Point of subjective equality (PSE) and difference limen (DL) for Parkinson’s disease(with and without DST) (PD; n = 25) and HCs (n = 25) across intact and scrambled BM conditions (Mean ± Standard Deviation).
| Condition | Group | PSE | DL |
|---|---|---|---|
| Intact BM | PD without DST | −0.31 ± 97.60* | 542.73 ± 202.32 |
| PD with DST | −99.97 ± 81.46 | 532.26 ± 205.74 | |
| HCs | −88.92 ± 78.09 | 630.16 ± 247.80 | |
| Scrambled BM | PD without DST | −14.18 ± 51.63* | 681.17 ± 319.02 |
| PD with DST | −54.72 ± 78.40 | 664.06 ± 275.17 | |
| HCs | −59.53 ± 56.28 | 672.69 ± 318.46 |
*In comparison with PD without DST and HCs: P < 0.05.
Figure 1Scrambled point-light walkers, and intact point-light walkers were used in the present study, including upright and inverted stimuli.
Figure 2Psychometric function for observers in scrambled BM condition with a standard duration of 1000 ms. The vertical solid-line arrow and long dash-line arrow show a significant negative PSE in HCs and PD patients with regular DST. However,the vertical short dash-line arrow shows there was no significant negative PSE in PD patients without DST. The horizontal arrows indicate the DL.
Figure 3Duration discrimination results from experiment 1. The temporal dilation effect (i.e., minus PSE) of the upright biological motion stimuli was significantly larger than that of the inverted biological motion stimuli. The PSE of the scrambled biological motion stimuli in PD without DST and HCs were significantly different, but the PSE in PD with and without DST were not significantly different (*P < 0.05; n.s., not significant). Error bars show standard errors.
Figure 4Psychometric function for observers in intact BM condition with a standard duration of 1000 ms. The vertical solid-line arrow and long dash-line arrow show a significant negative PSE in HCs and PD patients with regular DST. However,the vertical short dash-line arrow shows there was a positive PSE in PD patients without DST. The horizontal arrows indicate the DL.
Figure 5Duration discrimination results from experiment 2. The temporal dilation effect (i.e., minus PSE) of the upright biological motion stimuli was significantly larger than that of the inverted biological motion stimuli. The PSE of the intact biological motion stimuli in PD without DST and HCs were significantly different, the PSE in PD with and without DST were also significantly different (*P < 0.05; n.s., not significant). Error bars show standard errors.
The correlation between PD patients (both with and without DST) with various factors.
| Correlation | Age | Disease duration | H-Y stage | MMSE | VFT | DS(f) | DS(b) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| r |
| r |
| r |
| r |
| r |
| r |
| r |
| ||
| PSE (Intact BM) | on | −0.01 | 0.98 | −0.24 | 0.25 | 0.03 | 0.90 | 0.13 | 0.54 | −0.01 | 0.97 | 0.19 | 0.36 | 0.09 | 0.66 |
| off | 0.07 | 0.75 | −0.05 | 0.80 | −0.06 | 0.77 | 0.39 | 0.06 | −0.07 | 0.73 | 0.22 | 0.30 | 0.05 | 0.83 | |
| PSE (Scrambled BM) | on | 0.24 | 0.26 | 0.24 | 0.24 | 0.24 | 0.26 | 0.27 | 0.20 | −0.06 | 0.78 | 0.14 | 0.50 | 0.05 | 0.82 |
| off | 0.28 | 0.17 | 0.32 | 0.12 | 0.33 | 0.11 | 0.19 | 0.37 | −0.28 | 0.17 | −0.17 | 0.41 | −0.13 | 0.55 | |
“on” stands for with DST; “off” stands for without DST.
PD patients with and without DST in details.
| Regular DST | Time since last medicine intake (h) | ||||
|---|---|---|---|---|---|
| Levodopa + Benserazide (mg/d) | Other anti-parkinsonian medicine | L-dopa Equivalent Dose[ | |||
| DA agonist (mg/d) | MAOB inhibitors (mg/d) | Amantadine (mg/d) | |||
| 250 | — | 10 (selegiline) | 300 | 600 | 16 |
| 500 | 50 (piribedil) | — | — | 450 | 16 |
| 375 | 100(piribedil) | — | — | 400 | 17 |
| — | — | — | 300 | 300 | 20 |
| 500 | 100(piribedil) | — | — | 500 | 18 |
| 125 | — | — | 300 | 400 | 18 |
| 187.5 | — | — | — | 150 | 17 |
| 250 | — | — | 300 | 500 | 15 |
| 187.5 | — | — | 200 | 350 | 15 |
| 187.5 | 150(piribedil) | — | — | 300 | 15 |
| 375 | — | — | 300 | 600 | 18 |
| 375 | — | 20 (selegiline) | 200 | 700 | 15 |
| 250 | — | — | — | 200 | 16 |
| 625 | — | — | 300 | 800 | 15 |
| 375 | — | — | 200 | 500 | 18 |
| 250 | — | — | 300 | 500 | 15 |
| 500 | 100(piribedil) | — | 300 | 800 | 15 |
| 250 | 50(piribedil) | — | — | 250 | 17 |
| 125 | — | — | 200 | 300 | 18 |
| 187.5 | — | — | — | 150 | 16 |
| 500 | — | — | 300 | 700 | 18 |
| 187.5 | — | — | 200 | 350 | 24 |
| 500 | 0.75(pramipexole) | — | 300 | 775 | 16 |
| 375 | — | — | — | 300 | 20 |
| 187.5 | — | — | 200 | 350 | 18 |